Parmax Pharma Ltd.

PARMAX

₹38.54

6.61% (2.39)

Market Cap

₹14 Cr.

P/E

0.00

Key Ratios

Edit Ratio's

Market cap

14.00 Cr

Prom Holding

30.80 %

ROE (%)

-8,146

ROCE (%)

-82.25

Div Yield (%)

Sales

22.33 Cr

OPM (%)

-2.28 %

Debt to Equity

83.26

Edit Ratio's

About

Parmax Pharma Limited is a pharmaceutical company specializing in active pharmaceutical ingred… Read more

Low

52W Range

High

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statementNew

Edit rows

Forensics

6 Yes

Positive for this company

1 Neutral

Neutral for this company

8 No

Negative for this company

2 No Data

Insufficient data to analyse

Accounting & Shareholding

Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Promoter Holding

Promoter has not sold any shares in the last 90 days
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales
Contingent Liabilities

Unable to calculate due to limited data

Price & Performance

ROE

Asset turnover is responsible for roe increase over last 10 years
Working Capital

Working capital of the company seems to be under control
Capex vs ROCE

Roce of the company has decreased even without significant capex
Debt

Company might have issues servicing its debt
Share price

Share price has increased over last 10 years but more due to rerating
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong
Balance Sheet Strength

Balance sheet is weak and might have solvency issues
Current vs Historic Valuation

Unable to calculate due to limited data

Revenue mix

Product Wise Break-Up

Peer Comparison

FAQs on Parmax Pharma Ltd. Business

What does Parmax Pharma do?

Parmax Pharma Limited excels in producing active pharmaceutical ingredients (API) and providing Contract Manufacturing Operations (CMO) with a strong emphasis on quality by design methods in compliance with cGMP standards.

Who are the competitors of Parmax Pharma?

Parmax Pharma major competitors are Emmessar Biotech&Nut, Venmax Drugs&Pharma, Link Pharma Chem, Saroja Pharma Ind, Ortin Global, Colinz Laboratories, Decipher Labs.
Market Cap of Parmax Pharma is ₹14 Crs.
While the median market cap of its peers are ₹14 Crs.

Is Parmax Pharma financially stable compared to its competitors?

Parmax Pharma seems to be less financially stable compared to its competitors.
Altman Z score of Parmax Pharma is -0.49 and is ranked 6 out of its 8 competitors.

View FAQ's On Shareprice

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Parmax Pharma Ltd.

Parmax Pharma Ltd.

Key Ratios

About

Timeline

Company Timeline

6 Yes

1 Neutral

8 No

2 No Data

Accounting & Shareholding

Depreciation Effect

Other Income

Pledge

Retail Holding

Promoter Holding

Revenue Recognition

Contingent Liabilities

Price & Performance

ROE

Working Capital

Capex vs ROCE

Debt

Share price

Sales Growth

Margin Stability

ROCE Strength

Balance Sheet Strength

Current vs Historic Valuation

Product Wise Break-Up

UNLOCK PREMIUM

What does Parmax Pharma do?

Who are the competitors of Parmax Pharma?

Is Parmax Pharma financially stable compared to its competitors?

SIGN UP FOR FREE